Project Grant R44DC017625
- Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Research Foundation for the State University of New York a $637,554 Project Grant (CFDA 93.286: Discovery and Applied Research for Technological Innovations to Improve Human Health) effective April 1, 2026, through March 31, 2030, to develop AudioSight, an innovative smartphone-based system for objective assessment of sound sensitivity and tolerance (SST) disorders. The project addresses a...
- Grant Award Summary The National Institute on Aging, under the Aging Research program (CFDA 93.866), awarded $4.59 million to the Regents of the University of California, San Francisco for a four-year project (September 5, 2025 through August 31, 2029) to develop and validate automated speech analysis technology for early detection of Alzheimer's disease (AD). The primary deliverable is an AD-specific speech profile utilizing machine learning algorithms to identify linguistic and acoustic...
- Federal Project Grant Award Summary Emory University received a $1,038,672 Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), effective September 18, 2025, through August 31, 2028. The research project will develop and validate acoustic and physiological outcome measures for diagnosing Adductor Laryngeal Dystonia (ADLD), a neurological voice disorder...
- Federal Project Grant Award Summary The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $663,904 Project Grant to the University of Pittsburgh on March 13, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The grant funds research through February 28, 2031, to evaluate the effectiveness of Acceptance and Commitment Therapy (ACT) for Aphasia—an integrated, aphasia-adapted counseling and communication strategy...
- Federal Project Grant Award Summary Award Overview: The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded a $679,182 Project Grant to Trustees of Boston University beginning September 1, 2025, and concluding August 31, 2030, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). Products and Services: This project will develop advanced computational models that integrate multimodal neuroimaging data—including structural magnetic...
- This Cooperative Agreement award from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $1 million to Itherapy, LLC of Martinez, California to develop an evaluative artificial speech intelligence and autism screener system called EASI-AS. The system aims to improve treatment for children with communication impairments by providing specialists and parents with accurate, efficient reports on speech and language evaluations along with...
- Federal Project Grant Award Summary San Diego State University Research Foundation received a $211,287 Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), effective May 1, 2026, through April 30, 2031. This research initiative addresses the critical gap in evidence-based clinical language assessment for autistic young adults, particularly those with...
- Federal Project Grant Award Summary The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded Northeastern University a $778,740 Project Grant on August 1, 2025, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to develop validated assessment protocols for differentiating Childhood Apraxia of Speech (CAS) and dysarthria in preschool-aged children. The five-year project (concluding July 31, 2030) addresses a critical clinical...
- Federal Project Grant Award Summary New York University School of Medicine received a $721,226 project grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), effective June 1, 2026, through May 31, 2031. The grant funds the development and validation of the Wireless Ambulatory Voice Evaluator (WAVE), an innovative miniaturized wearable device designed to enable real-world...
- Federal Project Grant Award Summary The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded $187,297 to Henry Ford Health + Michigan State University Health Sciences under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) for a three-year project period (June 1, 2025 – May 31, 2028). This project focuses on identifying acoustic and perceptual mechanisms underlying speech amplification devices for individuals with Parkinson's disease...
AUTOMATED OBJECTIVE OUTCOME MEASURES FOR CLINICAL USE IN DYSARTHRIA - ABSTRACT / SUMMARY THE INABILITY TO ENGAGE IN SPOKEN COMMUNICATION IS AMONG THE MOST DEBILITATING OF ALL HUMAN CONDITIONS. IN THE FIELD OF COMMUNICATION DISORDERS, A SPEECH-LANGUAGE PATHOLOGIST'S (SLP'S) PERCEPTUAL EVALUATION OF THE QUALITY OF SPEECH PRODUCTION IS THE GOLD STANDARD FOR ASSESSMENT AND FOR DOCUMENTING TREATMENT PROGRESS. HOWEVER, DECADES OF RESEARCH HAVE CONFIRMED THAT AUDITORY-PERCEPTUAL JUDGMENTS OF SPEECH ARE INHERENTLY BIASED, WHICH COMPROMISES RELIABILITY. THE REASON IS THAT THE HUMAN PERCEPTUAL SYSTEM IS ADAPTIVE, WITH PERCEPTUAL BIAS ACCRUED BY WORKING WITH AN INDIVIDUAL ACROSS MULTIPLE TREATMENT SESSIONS, OR BY WORKING WITH PATIENT POPULATIONS ACROSS A CAREER. THUS, TO RELIABLY DOCUMENT TREATMENT OUTCOMES SUBJECTIVELY, IT IS NECESSARY TO INVOLVE MULTIPLE, UNFAMILIAR LISTENERS. THIS IS UNTENABLE IN MOST CLINICAL SETTINGS, WHICH MEANS THAT SUBJECTIVE IMPRESSIONS ARE MADE BY THE TREATING CLINICIANS. THE RELIANCE ON SUBJECTIVE EVALUATION DIRECTLY UNDERMINES THE QUALITY OF CLINICAL PRACTICE AND A CLINICIAN'S ABILITY TO DEMONSTRATE THE EFFICACY OF AN INTERVENTION. AURAL ANALYTICS HAS DEVELOPED NEW OBJECTIVE ACOUSTIC SPEECH METRICS THAT RELIABLY MEASURE SPEECH IN POPULATIONS WITH NEUROLOGICAL DISORDERS. ITS TECHNOLOGY IS BASED ON A STRONG SCIENTIFIC PREMISE AND HAS BEEN ADOPTED EARLY BY PHARMACEUTICAL COMPANIES AND NEUROLOGISTS IN CLINICAL RESEARCH. AURAL ANALYTICS HAS COLLECTED AND ANALYZED TENS OF THOUSANDS OF SPEECH SAMPLES USING ITS TECHNOLOGY, AND THE RESULTS ARE DEMONSTRATING THAT ITS MEASURES ARE ROBUST, RELIABLE, AND MORE SENSITIVE TO LONGITUDINAL CHANGES IN SPEECH THAN ARE OTHER EXISTING OUTCOME MEASURES. WE SUCCESSFULLY COMPLETED A PHASE I SBIR PROJECT WITH THE AIM OF TRANSLATING OUR TECHNOLOGY TO SLP CLINICAL PRACTICE. THIS PHASE II PROPOSAL NATURALLY BUILDS ON OUR PREVIOUS WORK BY CONNECTING THE AUTOMATED APP-BASED OUTCOME MEASURES COMPLETED IN PHASE I TO THREE COMPLEMENTARY CLINICAL BENCHMARKS. SPECIFICALLY, SA1 WILL VALIDATE THE AURAL ANALYTICS SPEECH MEASURES AGAINST THE AMERICAN SPEECH-LANGUAGE-HEARING ASSOCIATION'S (ASHA) FUNCTIONAL COMMUNICATION MEASURES (FCM) FOR MOTOR SPEECH; THE SENTENCE INTELLIGIBILITY TEST; AND EXPERT RATINGS OF SPEECH CHARACTERISTICS. IN ADDITION, AGE AND GENDER-BASED NORMS FOR ALL OBJECTIVE MEASURES WILL BE OBTAINED FROM COLLECTION OF DATA FROM 600 NEW HEALTHY PARTICIPANTS. IN SA2, AURAL ANALYTICS WILL CONDUCT A USABILITY STUDY WITH PRACTICING SPEECH-LANGUAGE PATHOLOGISTS TO ASSESS REAL WORLD UTILITY AND REFINE THE USER EXPERIENCE. THE DELIVERABLE OF THIS PROPOSAL WILL BE A FULLY-FUNCTIONAL MOBILE APPLICATION, VALIDATED BY PRACTICING SLPS IN A CLINICAL SETTING, WITH REAL TIME SPEECH OUTCOME METRICS VALIDATED WITH RESPECT TO EXISTING COMMUNITY-ACCEPTED MEASURES. THIS WILL RESULT IN OBJECTIVE OUTCOMES THAT FIT INTO THE WORKFLOW OF THE PROFESSIONAL STANDARD, THEREBY EXPEDITING OUR PATH TO COMMERCIALIZATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($178k) | 11/14/24 | ||
| Not listed | $0 | 3/29/24 | ||
| Not listed | $0 | 3/29/24 | ||
| Not listed | $0 | 3/21/24 | ||
| Not listed | $0 | 3/21/24 |